Loading clinical trials...
Loading clinical trials...
A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of UK-500,001 Dry Powder For Inhalation (DPI) In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).
This initial proof of concept, phase II study aims to assess the safety and efficacy of UK-500,001 for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease.
Age
40 - 80 years
Sex
ALL
Healthy Volunteers
No
Pfizer Investigational Site
La Plata, Buenos Aires, Argentina
Pfizer Investigational Site
Vicente López, Buenos Aires, Argentina
Pfizer Investigational Site
Rosario, Santa Fé, Argentina
Pfizer Investigational Site
Buenos Aires, Argentina
Pfizer Investigational Site
Buenos Aires, Argentina
Pfizer Investigational Site
Camperdown, New South Wales, Australia
Pfizer Investigational Site
Clayton, Victoria, Australia
Pfizer Investigational Site
Nedlands, Western Australia, Australia
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Red Deer, Alberta, Canada
Start Date
November 1, 2005
Completion Date
September 1, 2006
Last Updated
July 23, 2007
324
Estimated participants
UK-500,001
DRUG
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05050591